Adalvo is thrilled to announce the expansion of its partnership with Teva, signing a licensing deal for a blockbuster small molecule in the oncology segment aimed at addressing rare diseases with limited treatment options.
The total market value of the signed products exceeds $1.0 billion, reflecting the immense potential and impact of this collaboration. These products, generics of innovative/originator products, are currently selling at a value exceeding $1.0 billion. Through this partnership, Adalvo and Teva have successfully closed 5 deals in 2023, further solidifying Adalvo's position in the pharmaceutical industry.
Anil Okay, CEO at Adalvo, conveyed his enthusiasm for the collaboration by saying, "Teva's global leadership in generics and biopharmaceuticals perfectly complements our mission to expand Adalvo's presence and improve patient access to vital medications. This partnership signifies a significant step forward in Adalvo's commitment to providing innovative healthcare solutions, bringing quality therapies to patients around the world, and making a positive impact on their lives."
With this partnership Adalvo will continue to embark on our journey, driven by unwavering commitment to quality, compliance, and the betterment of patient lives.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
email@example.com – Central & Eastern Europe, Russia & CIS
firstname.lastname@example.org- North Europe, APAC, MENA & Israel
email@example.com – Brazil
firstname.lastname@example.org - LATAM (exc. Brazil) & South Europe
email@example.com – Europe
firstname.lastname@example.org – UK/Ireland, North America & South Africa
email@example.com - LATAM (exc. Brazil)
firstname.lastname@example.org - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.